RA Capital Nexus Fund II, L.P.
SEC-identified person · CIK 1825376 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Silverback Therapeutics, Inc. SPRY | Director | filed 2022–2026 |
| Acrivon Therapeutics, Inc. ACRV | Director | filed 2022–2026 |
| Pepgen Inc. PEPG | Director | filed 2022–2026 |
| Lenz Therapeutics, Inc. LENZ | Director | filed 2024–2026 |
| Janux Therapeutics, Inc. JANX | Director | filed 2023–2026 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2021–2026 |
| Acumen Pharmaceuticals, Inc. ABOS | Director | filed 2021–2026 |
| Hemab Therapeutics Holdings, Inc. COAG | Director | filed 2026–2026 |
| Werewolf Therapeutics, Inc. HOWL | Director | filed 2024–2025 |
| AN2 Therapeutics, Inc. ANTX | Officer | filed 2022–2024 |
| Boundless Bio, Inc. BOLD | Officer | filed 2024–2024 |
| Icosavax, Inc. ICVX | Director | filed 2021–2024 |
| Dice Therapeutics, Inc. DICE | Director | filed 2021–2023 |
| Cytek Biosciences, Inc. CTKB | Director | filed 2021–2022 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.